Equities analysts forecast that Accelerate Diagnostics Inc (NASDAQ:AXDX) will post ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Accelerate Diagnostics’ earnings, with estimates ranging from ($0.42) to ($0.36). Accelerate Diagnostics posted earnings of ($0.43) per share during the same quarter last year, which suggests a positive year over year growth rate of 7%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, August 8th.

On average, analysts expect that Accelerate Diagnostics will report full year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.68) to ($1.47). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($1.64) to ($1.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Accelerate Diagnostics.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Accelerate Diagnostics had a negative return on equity of 130.94% and a negative net margin of 1,352.80%. The firm had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $2.12 million.

A number of research analysts have issued reports on the company. ValuEngine raised Zillow Group from a “hold” rating to a “buy” rating in a research note on Thursday, July 11th. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. BidaskClub cut Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, BTIG Research reiterated a “hold” rating on shares of Accelerate Diagnostics in a research note on Sunday, May 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $19.67.

A number of hedge funds have recently modified their holdings of AXDX. Amundi Pioneer Asset Management Inc. boosted its position in Accelerate Diagnostics by 33.0% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 991,090 shares of the medical research company’s stock valued at $11,397,000 after buying an additional 246,000 shares during the period. FMR LLC raised its stake in Accelerate Diagnostics by 16.1% in the first quarter. FMR LLC now owns 857,069 shares of the medical research company’s stock worth $18,016,000 after buying an additional 118,620 shares in the last quarter. Stifel Financial Corp raised its stake in Accelerate Diagnostics by 24.6% in the fourth quarter. Stifel Financial Corp now owns 556,763 shares of the medical research company’s stock worth $6,365,000 after buying an additional 110,034 shares in the last quarter. Chicago Capital LLC raised its stake in Accelerate Diagnostics by 10.6% in the second quarter. Chicago Capital LLC now owns 546,279 shares of the medical research company’s stock worth $12,499,000 after buying an additional 52,460 shares in the last quarter. Finally, Griffin Asset Management Inc. raised its stake in Accelerate Diagnostics by 11.1% in the first quarter. Griffin Asset Management Inc. now owns 484,871 shares of the medical research company’s stock worth $10,192,000 after buying an additional 48,352 shares in the last quarter. 50.58% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:AXDX traded up $0.09 on Friday, reaching $19.21. The company’s stock had a trading volume of 495 shares, compared to its average volume of 196,599. Accelerate Diagnostics has a 1-year low of $10.23 and a 1-year high of $24.75. The company has a current ratio of 25.36, a quick ratio of 24.03 and a debt-to-equity ratio of 2.86. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -11.80 and a beta of 2.84. The stock’s 50-day moving average price is $20.60.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Story: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.